Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
Research reports from Y.Q. Liang and co-authors provide new insights into Alzheimer disease
May 18th, 2008
According to a study from Shanghai, People's Republic of China, "(1) Huperzine A, a promising therapeutic agent for Alzheimer's disease (AD), was tested for its effects on cholinergic and monoaminergic dysfunction induced by injecting beta-amyloid peptide-(1 - 40) into nucleus basalis magnocellularis of the rat. (2) Bilateral injection of 10 mu g beta-amyloid peptide-(1 - 40) into nucleus basalis magnocellularis produced local deposits of amyloid plaque and functional abnormalities detected by microdialysis." "In medial prefrontal cortex, reductions in the basal levels and stimulated release of acetylcholine, dopamine, norepinephrine, and 5-hydroxytryptamine were...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-18)
|
